Cargando…
Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning
PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planni...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425940/ https://www.ncbi.nlm.nih.gov/pubmed/34339590 http://dx.doi.org/10.1002/acm2.13376 |
_version_ | 1783749944553766912 |
---|---|
author | Tsubouchi, Toshiro Hamatani, Noriaki Takashina, Masaaki Wakisaka, Yushi Ogawa, Atsuhiro Yagi, Masashi Terasawa, Ayumi Shimazaki, Kazuyuki Chatani, Masashi Mizoe, Jun’etsu Kanai, Tatsuaki |
author_facet | Tsubouchi, Toshiro Hamatani, Noriaki Takashina, Masaaki Wakisaka, Yushi Ogawa, Atsuhiro Yagi, Masashi Terasawa, Ayumi Shimazaki, Kazuyuki Chatani, Masashi Mizoe, Jun’etsu Kanai, Tatsuaki |
author_sort | Tsubouchi, Toshiro |
collection | PubMed |
description | PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planning target volume (bsPTV) based on the effect of the markers on dose distribution and analysis of target movements. MATERIALS AND METHODS: Gafchromic EBT3 film was used to measure dose perturbations caused by markers. First, the relationships between the irradiated film density and absolute dose with different linear energy transfer distributions within a spread‐out Bragg peak (SOBP) were confirmed. Then, to derive the effect of markers, two types of markers, including GA, were placed at the proximal, center, and distal depths within the same SOBP, and dose distributions behind the markers were measured using the films. The amount of internal motion of prostate was derived from irradiation results and analyzed to determine the margins of the bsPTV. RESULTS: The linearity of the film densities against absolute doses was constant within the SOBP and the amount of dose perturbations caused by the markers was quantitatively estimated from the film densities. The dose perturbation close behind the markers was smallest (<10% among depths within the SOBP regardless of types of markers) and increased with depth. The effect of two types of GAs on dose distributions was small and could be ignored in the treatment planning. Based on the analysis results of internal motions of prostate, required margins of the bsPTV were found to be 8, 7, and 7 mm in left–right (LR), anterior–posterior (AP), and superior–inferior (SI) directions, respectively. CONCLUSION: We evaluated the dose reductions caused by markers and determined the margins of the bsPTV, which was applied to the treatment using fiducial markers, using the analysis results of prostate movements. |
format | Online Article Text |
id | pubmed-8425940 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84259402021-09-13 Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning Tsubouchi, Toshiro Hamatani, Noriaki Takashina, Masaaki Wakisaka, Yushi Ogawa, Atsuhiro Yagi, Masashi Terasawa, Ayumi Shimazaki, Kazuyuki Chatani, Masashi Mizoe, Jun’etsu Kanai, Tatsuaki J Appl Clin Med Phys Radiation Oncology Physics PURPOSE: Carbon ion radiotherapy for prostate cancer was performed using two fine needle Gold Anchor (GA) markers for patient position verification in Osaka Heavy Ion Medical Accelerator in Kansai (Osaka HIMAK). The present study examined treatment plans for prostate cases using beam‐specific planning target volume (bsPTV) based on the effect of the markers on dose distribution and analysis of target movements. MATERIALS AND METHODS: Gafchromic EBT3 film was used to measure dose perturbations caused by markers. First, the relationships between the irradiated film density and absolute dose with different linear energy transfer distributions within a spread‐out Bragg peak (SOBP) were confirmed. Then, to derive the effect of markers, two types of markers, including GA, were placed at the proximal, center, and distal depths within the same SOBP, and dose distributions behind the markers were measured using the films. The amount of internal motion of prostate was derived from irradiation results and analyzed to determine the margins of the bsPTV. RESULTS: The linearity of the film densities against absolute doses was constant within the SOBP and the amount of dose perturbations caused by the markers was quantitatively estimated from the film densities. The dose perturbation close behind the markers was smallest (<10% among depths within the SOBP regardless of types of markers) and increased with depth. The effect of two types of GAs on dose distributions was small and could be ignored in the treatment planning. Based on the analysis results of internal motions of prostate, required margins of the bsPTV were found to be 8, 7, and 7 mm in left–right (LR), anterior–posterior (AP), and superior–inferior (SI) directions, respectively. CONCLUSION: We evaluated the dose reductions caused by markers and determined the margins of the bsPTV, which was applied to the treatment using fiducial markers, using the analysis results of prostate movements. John Wiley and Sons Inc. 2021-08-02 /pmc/articles/PMC8425940/ /pubmed/34339590 http://dx.doi.org/10.1002/acm2.13376 Text en © 2021 The Authors. Journal of Applied Clinical Medical Physics published by Wiley Periodicals LLC on behalf of American Association of Physicists in Medicine. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Radiation Oncology Physics Tsubouchi, Toshiro Hamatani, Noriaki Takashina, Masaaki Wakisaka, Yushi Ogawa, Atsuhiro Yagi, Masashi Terasawa, Ayumi Shimazaki, Kazuyuki Chatani, Masashi Mizoe, Jun’etsu Kanai, Tatsuaki Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title | Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title_full | Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title_fullStr | Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title_full_unstemmed | Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title_short | Carbon ion radiotherapy using fiducial markers for prostate cancer in Osaka HIMAK: Treatment planning |
title_sort | carbon ion radiotherapy using fiducial markers for prostate cancer in osaka himak: treatment planning |
topic | Radiation Oncology Physics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8425940/ https://www.ncbi.nlm.nih.gov/pubmed/34339590 http://dx.doi.org/10.1002/acm2.13376 |
work_keys_str_mv | AT tsubouchitoshiro carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT hamataninoriaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT takashinamasaaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT wakisakayushi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT ogawaatsuhiro carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT yagimasashi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT terasawaayumi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT shimazakikazuyuki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT chatanimasashi carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT mizoejunetsu carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning AT kanaitatsuaki carbonionradiotherapyusingfiducialmarkersforprostatecancerinosakahimaktreatmentplanning |